Reata Pharmaceuticals Income Statement 2022-2011 | RETA

Brief overview of revenue and earnings at Reata Pharmaceuticals

The conclusions below are based on five years of reported results. According to figures from Reata Pharmaceuticals, revenue changed from 10 million dollars to 2.2 million dollars over five years. The total change was −77.8%, with a CAGR of approximately −26%. The negative rate indicates weakening core operations.

Over the period, EBITDA shifted from $437 thousand to $1.1 million, a change of +158.6%. The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from 4.4% to 51%. A wider margin confirms stronger operating efficiency.

Net income moved from −$47.7 million at the start to −$312 million at the end. Profitability deteriorated further over the five years.

Market value was $682 million at the start and $1.6 billion at the end. The higher valuation contrasts with weaker financial performance.

Conclusion

The results present an uneven picture without one dominant signal. The strongest signals are an improving EBITDA margin. The weaker side of the profile includes declining net profitability and a softer top-line trend. The key question is whether sales can be converted into sustainable profit.